Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival

Minoo Battiwalla, MD, MS, Fang Yin, MD, Sawa Ito, Xingmin Feng, PhD, Fariba Chinian, M.S., J. Joseph Melenhorst, PhD, Eleftheria K Koklanaris, BSN, Marianna Sabatino, David Stroncek, MD, Leigh Samsel, MS, Jeffrey K. Klotz, MD, Nancy F. Hensel, Pamela Robey, PhD, A. John Barrett, MD

Blood (2013) 122 (21): 3282.

https://doi.org/10.1182/blood.V122.21.3282.3282

Published: 2013

Journal Articles

Contrast Enhanced Cardiac CT Detects Coronary Artery Disease In 44% Of Asymptomatic Long-Term Adult Allogeneic Stem Cell Transplant Survivors

Natasha A Jain, MD, Marcus Y Chen, MD, Sujata Shanbhag, MD, Kit Lu, MD, Priyanka A Pophali, MD, Sawa Ito, Eleftheria K Koklanaris, BSN, Christopher S. Hourigan, MD, PhD, A. John Barrett, MD, Minoo Battiwalla, MD, MS

Blood (2013) 122 (21): 2080.

https://doi.org/10.1182/blood.V122.21.2080.2080

Published: 2013

Journal Articles

Post-Transplant Pulmonary Function Abnormalities Normalize in Survivors by the Second Decade After Allogeneic Stem Cell Transplantation

Natasha A Jain, MD, Eleftheria K. Koklanaris, BSN, Kamna Chawla, MD, MS, Priyanka A Pophali, MD, Jeffrey K. Klotz, MD, Christopher S. Hourigan, MD, PhD, Bipin N. Savani, MD, Sawa Ito, MD, A. John Barrett, MD, FRCP, Minoo Battiwalla, MD, MS

Blood (2012) 120 (21): 1967.

https://doi.org/10.1182/blood.V120.21.1967.1967

Published: 2012

Journal Articles

Second Stem Cell Transplantation (SCT) for Relapsed Leukemia Provides Only Modest Prolongation of Survival

Zachariah A. McIver, DO, Thomas Hughes, Pharm D, Sawa Ito, MD, Minoo Battiwalla, MD, MS, Eleftheria K. Koklanaris, BSN, Janice Haggerty, RN, Nancy F. Hensel, BS, A. John Barrett, MD

Blood (2011) 118 (21): 2001.

https://doi.org/10.1182/blood.V118.21.2001.2001

Published: 2011

Journal Articles

Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant,

Priyanka A Pophali, MD, Kamna Chawla, MD, MS, Eleftheria K. Koklanaris, BSN, Avan Antia, Simar Chawla, Sawa Ito, MD, Jeffrey K. Klotz, MD, Robert Q. Le, MD, PhD, A. John Barrett, MD, FRCP, Minoo Battiwalla, MD, MS

Blood (2011) 118 (21): 4099.

https://doi.org/10.1182/blood.V118.21.4099.4099

Published: 2011

Journal Articles

Impact of Tyrosine Kinase Inhibitor (TKI) in Chronic Myeloid Leukemia (CML) Relapsing After T Cell Depleted Allogeneic Stem Cell Transplantation (SCT)

Sawa Ito, MD, Minoo Battiwalla, MD, MS, Eleftheria K. Koklanaris, BSN, Jeanine Superata, Richard Childs, MD, A. John Barrett, MD

Blood (2011) 118 (21): 2762.

https://doi.org/10.1182/blood.V118.21.2762.2762

Published: 2011

Journal Articles

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

Agnes S. M. Yong, MD, PhD, Keyvan Keyvanfar, BS, Rhoda Eniafe, BS, Bipin N. Savani, MD, Katayoun Rezvani, MD, PhD, Aarthi Shenoy, MD, Eleftheria K. Koklanaris, BSN, Laura Musse, MSN, Theresa Donohue, MS, Quan Le, MD, PhD, John M. Goldman, MD, A. John Barrett, MD

Blood (2008) 112 (11): 1107.

https://doi.org/10.1182/blood.V112.11.1107.1107

Published: 2008

NARROW

Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival

Contrast Enhanced Cardiac CT Detects Coronary Artery Disease In 44% Of Asymptomatic Long-Term Adult Allogeneic Stem Cell Transplant Survivors

Post-Transplant Pulmonary Function Abnormalities Normalize in Survivors by the Second Decade After Allogeneic Stem Cell Transplantation

Second Stem Cell Transplantation (SCT) for Relapsed Leukemia Provides Only Modest Prolongation of Survival

Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant,

Impact of Tyrosine Kinase Inhibitor (TKI) in Chronic Myeloid Leukemia (CML) Relapsing After T Cell Depleted Allogeneic Stem Cell Transplantation (SCT)

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival

Contrast Enhanced Cardiac CT Detects Coronary Artery Disease In 44% Of Asymptomatic Long-Term Adult Allogeneic Stem Cell Transplant Survivors

Post-Transplant Pulmonary Function Abnormalities Normalize in Survivors by the Second Decade After Allogeneic Stem Cell Transplantation

Second Stem Cell Transplantation (SCT) for Relapsed Leukemia Provides Only Modest Prolongation of Survival

Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant,

Impact of Tyrosine Kinase Inhibitor (TKI) in Chronic Myeloid Leukemia (CML) Relapsing After T Cell Depleted Allogeneic Stem Cell Transplantation (SCT)

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only